Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02687984 · ClinicalTrials.gov registry record · Phase 1
PK, Safety, and Tolerability Study of RBP-7000 of Different Molecular Weight Polymer in Subjects With Schizophrenia
A Phase 1 study of Schizophrenia, sponsored by Indivior.
- Completed
- Registry status
- Phase 1
- Development phase
- 44
- Enrollment target
- 2
- Study locations
NCT02687984: Completed Phase 1 study of Schizophrenia, sponsored by Indivior.
NCT02687984 is a Phase 1 study of Schizophrenia that has completed, run by Indivior. The registered enrollment target is 44 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (80% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02687984, a Phase 1 study of Schizophrenia, has completed, sponsored by Indivior.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 44 participants
- Enrollment target
- 2
- Study locations
Study Summary
Primary Objective: To assess the relative bioavailability of RBP-7000 formulated with 2 different molecular weights (MW) (low and high MW as test treatments) of poly (DL-lactide-co-glycolide) with a carboxylic acid end group (PLGH) polymer compared to intermediate MW PLGH polymer following single subcutaneous (SC) injection of RBP-7000 in subjects with stable schizophrenia. Secondary Objective: To evaluate the safety and tolerability of single SC injections of RBP-7000 using a PLGH polymer of 2 different MW (low and high MW as test treatments) compared to intermediate MW polymer in subjects with stable schizophrenia.
Primary Outcome
Maximum observed plasma concentration
Conditions Studied
Interventions
- DRUG RBP-7000
Study Locations (2)
California
- Collaborative Neuroscience Network, LLC - Garden Grove
- Collaborative Neuroscience Network - Torrance
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2016-02 |
| Est. Completion | 2016-05 |
| Phase | Phase 1 |
What the finished NCT02687984 record still lists
NCT02687984 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 44 participants, a relatively small participant target, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (80% lower).
The record links to 1 condition, with Schizophrenia appearing as the primary indexed condition, and to 1 intervention - of which RBP-7000 is the first listed.
NCT02687984 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT02687984 about?
NCT02687984 is a clinical study titled "PK, Safety, and Tolerability Study of RBP-7000 of Different Molecular Weight Polymer in Subjects With Schizophrenia". Primary Objective: To assess the relative bioavailability of RBP-7000 formulated with 2 different molecular weights (MW) (low and high MW as test treatments) of poly (DL-lactide-co-glycolide) with a carboxylic acid end group (PLGH) polymer compared to intermediate MW PLGH polymer following single su...
What is the current status of trial NCT02687984?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 44 participants. The study started on 2016-02. Estimated completion is 2016-05.
What conditions does trial NCT02687984 study?
This clinical trial studies the following conditions: Schizophrenia.
What interventions are being tested in trial NCT02687984?
The interventions under investigation include: RBP-7000 (DRUG).
Who is sponsoring clinical trial NCT02687984?
This trial is sponsored by Indivior, which has 37 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02687984 being conducted?
This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02687984's enrollment target sits among peer trials
44 230th of 315 higher than 84 of 315 other Schizophrenia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Schizophrenia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Tolerability of MDMA in Schizophrenia
RECRUITING · Phase 1
-
Imaging Synapses With [11C] UCB-J in the Human Brain
RECRUITING · Phase 1
-
A Study to Evaluate the Dose Levels, Safety, and Drug Levels of Single KarXT Intramuscular Injection in Participants With Schizophrenia
RECRUITING · Phase 1
-
Proposal To Develop A Rapid And Cost-Effective Diagnostic Test For Schizophrenia
RECRUITING · Phase 1
-
Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder
RECRUITING · Phase 1
-
Genetics of Cannabis Use Disorder and Cannabinoid Response in Humans
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02323945 · 44 participants · NA
Effects of Breathing Mild Bouts of Low Oxygen on Limb Mobility After Spinal Injury
- NCT03093909 · 44 participants · Phase 1
Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
- NCT03104491 · 44 participants · Phase 1
Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
- NCT03781765 · 44 participants · Phase 4
Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia